Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although several prior clinical trials testing SRC or COX2 inhibitors in patients with CRC have failed to show meaningful clinical activity48–53”
From A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAFV600E colorectal tumors (2023) · cites this paper as [52]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tournigand, C., André, T., Achille, E., Lledo, G., Flesh, M., Mery-Mignard, D., Quinaux, E., Couteau, C., Buyse, M., Ganem, G., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.113 · Cited by 2,915
Self-citation
Research works printed but not linked: 23
- Jemal, 2002, Cancer statistics, 2002, CA Cancer J Clin, 52, 23, 10.3322/canjclin.52.1.23 · DOI · Paper page
- Tournigand, 2006, OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer—a GERCOR study, J Clin Oncol, 24, 394, 10.1200/JCO.2005.03.0106 · DOI · Paper page
- de Gramont, 2000, Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer, J Clin Oncol, 18, 2938, 10.1200/JCO.2000.18.16.2938 · DOI · Paper page
- Goldberg, 2004, A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer, J Clin Oncol, 22, 23, 10.1200/JCO.2004.09.046 · DOI · Paper page
- Maindrault-Goebel, 2000, Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR), Ann Oncol, 11, 1477, 10.1023/A:1026520812351 · DOI
- Maindrault-Goebel, 2004, Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer, Ann Oncol, 15, 1210, 10.1093/annonc/mdh305 · DOI
- Maughan, 2003, Continuous vs intermittant chemotherapy for advanced colorectal cancer: preliminary results of the MRC Cr06b randomised trial, Lancet, 361, 457, 10.1016/S0140-6736(03)12461-0 · DOI · Paper page
- Raoul, 2005, Chimiothérapie des cancers colorectaux métastatiques: pourquoi ne pas arrêter quand elle marche?, Gastro Clin Biol
- Hull, 2000, Cyclooxygenase-2 expression in colorectal cancer liver metastases, Clin Exp Metastasis, 18, 21, 10.1023/A:1026553605636 · DOI
- Sano, 1995, Expression of cyclooxygenase-1 and -2 in human colorectal cancer, Cancer Res, 55, 3785
- Masferrer, 2000, Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors, Cancer Res, 60, 1306
- Oshima, 1996, Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2), Cell, 87, 803, 10.1016/S0092-8674(00)81988-1 · DOI · Paper page
- Oshima, 2001, Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor, Cancer Res, 61, 1733
- Sheng, 1997, Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2, J Clin Invest, 99, 2254, 10.1172/JCI119400 · DOI · Paper page
- Reddy, 2000, Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis, Cancer Res, 60, 293
- Yao, 2003, Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice, Cancer Res, 63, 586
- Smalley, 1999, Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: a population-based study, Arch Intern Med, 159, 161, 10.1001/archinte.159.2.161 · DOI · Paper page
- Giardiello, 1993, Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis, N Engl J Med, 328, 1313, 10.1056/NEJM199305063281805 · DOI · Paper page
- Steinbach, 2000, The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis, N Engl J Med, 342, 1946, 10.1056/NEJM200006293422603 · DOI · Paper page
- Labianca, 2006, Alternating versus continuous ‘FOLFIRI’ in advanced colorectal cancer (ACC); a randomized ‘GISCAD’ study, Proc Am Clin Oncol, 24, 147s
- Alexopoulos, 2006, Continuous versus intermittent chemotherapy in metastatic colorectal cancer, Proc Am Clin Oncol, 24, 166s
- Maindrault-Goebel, 2006, GERCOR OPTIMOX 2. A large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC). A GERCOR study, Proc Am Clin Oncol, 24, 147s
- Plantade, 2006, Chemothearpy-free intervals (CFI) in patients with metastatic colorectal cancer, Proc Am Clin Oncol, 24, 166s
Cited by
A review on oxaliplatin-induced peripheral nerve damage
Argyriou, A. A., Polychronopoulos, P., Iconomou, G., Chroni, E., & Kalofonos, H. P. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.01.003 · Cited by 330
Yamada, Y., Takahari, D., Matsumoto, H., Baba, H., Nakamura, M., Yoshida, K., Yoshida, M., Iwamoto, S., Shimada, K., Komatsu, Y., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70490-x · Cited by 248
Parseghian, C. M., Parikh, N. U., Wu, J. Y., Jiang, Z.-Q., Henderson, L., Tian, F., Pastor, B., Ychou, M., Raghav, K., Dasari, A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3138 · Cited by 67
“1months (34, 36), and an independent significant positive impact on OS (HR 1⁄4 0.”
BackgroundRuiz-Saenz, A., Atreya, C. E., Wang, C., Pan, B., Dreyer, C. A., Brunen, D., Prahallad, A., Muñoz, D. P., Ramms, D. J., Burghi, V., et al. (2023) · Nature Cancer · doi:10.1038/s43018-022-00508-5 · Cited by 39
Metadata
- Authors
- André, T., Tournigand, C., Mineur, L., Fellague-Chebra, R., Flesch, M., Mabro, M., Hebbar, M., Postel Vinay, S., Bidard, F. C., Louvet, C., & de Gramont, A.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2007-01
- Volume
- 18
- Issue
- 1
- Pages
- 77-81
- ISSN
- 0923-7534
- Cited by
- 39
- References
- 1
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 4721 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study. https://app.cochat.ai/papers/10.1093/annonc/mdl336
- The paper
- André, T., Tournigand, C., Mineur, L., Fellague-Chebra, R., Flesch, M., Mabro, M., Hebbar, M., Postel Vinay, S., Bidard, F. C., Louvet, C., & de Gramont, A. (2007). Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study. Annals of Oncology. https://doi.org/10.1093/annonc/mdl336
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.